Cataract with dry eye
Conditions
Interventions
experimental group:0.05% Cyclosporine Eye Drops II (Cycloome)
Sponsors
Shenyang Air Excellence Eye Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50-80 years; 2. Age-related cataract was diagnosed, and the indications for phacoemulsification (Phaco + IOL implantation) or femtosecond assisted cataract extraction surgery were met and the surgery was planned; 3. The preoperative diagnosis was dry eye, which met the diagnostic criteria of dry eye listed in the Chinese Expert Consensus on Dry Eye: Examination and Diagnosis (2020): (1) The patient complained of one of the subjective symptoms such as ocular dryness, foreign body sensation, burning sensation, fatigue, discomfort, eye redness and visual fluctuation, with a score of >= 7 on the China Dry Eye Questionnaire or >= 13 on the Ocular Surface Disease Index (OSDI). At the same time, patients with FBUT = 7 on the China Dry Eye Questionnaire or >= 13 on the OSDI; At the same time, patients with FBUT > 5 s and 5 mm/5 min and = 5 spots) can be used to diagnose dry eye; 4. Sign the informed consent, and cooperate to complete the examination, treatment and follow-up for 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients at high risk of intraoperative or postoperative complications; 2. History of ocular trauma, blepharitis, eye infection unrelated to dry eye within 3 months from enrollment, filamentous keratitis; Severe dry eye, Sjogren's syndrome, allergic conjunctivitis, active ocular surface diseases, history of viral keratitis, history of corneal surgery, iritis, uveitis, history of corneal refractive surgery, pterygium, glaucoma, fundus diseases under treatment, systemic immune-related diseases, etc.; 3. Patients with incomplete eyelid closure, double eyelid surgery or other eyelid plastic surgery; 4. Use hormones, non-steroidal anti-inflammatory drugs, immunosuppressants and other drugs that may affect the study within 1 month before surgery; 5. Allergic to the drugs used in this study; 6. Patients with severe primary diseases of liver, kidney and hematopoietic system or mental disorders; 7. Failure to complete the 3-month follow-up; 8. Participating in other clinical trials or lost patients during follow-up; 9. The patient has any other conditions that the doctor considers impossible to enroll in the study. 10. Candidates who participated in clinical trials of other drugs or medical devices within 1 month before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Keratograph;OSDI, ocular surface disease index;wave front aberration; | — |
Countries
China
Contacts
Public ContactJinsong Zhang
Shenyang Air Excellence Eye Hospital
Outcome results
None listed